| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Cell Biology and
Immunology, Duke University Medical Center, Durham, NC 27710
Glucose-regulated protein 94 (GRP94/gp96), the endoplasmic reticulum heat shock protein 90 paralog, elicits both innate and adaptive immune responses. Regarding the former, GRP94/gp96 stimulates APC cytokine expression and dendritic cell maturation. The adaptive component of GRP94/gp96 function reflects a proposed peptide-binding activity and, consequently, a role for native GRP94/gp96-peptide complexes in cross-presentation. It is by this mechanism that tumor-derived GRP94/gp96 is thought to suppress tumor growth and metastasis. Recent data have demonstrated that GRP94/gp96-elicited innate immune responses can be sufficient to suppress tumor growth and metastasis. However, the immunological processes activated in response to tumor Ag-negative sources of GRP94/gp96 are currently unknown. We have examined the in vivo immunological response to nontumor sources of GRP94/gp96 and report that administration of syngeneic GRP94/gp96- or GRP94/gp96-N-terminal domain-secreting KBALB fibroblasts to BALB/c mice stimulates CD11b+ and CD11c+ APC function and promotes bystander activation of CD4+ T cell Th1 cytokine production. Only modest activation of CD8+ T cell or NK cell cytolytic function was observed. The GRP94/gp96-dependent induction of CD4+ T cell cytokine production was markedly inhibited by carrageenan, indicating an essential role for APC in this response. These results identify the bystander activation of CD4+ T lymphocytes as a previously unappreciated immunological consequence of GRP94/gp96 administration and demonstrate that GRP94/gp96-elicited alterations in the in vivo cytokine environment influence the development of CD4+ T cell effector functions, independently of its proposed function as a peptide chaperone.
This article has been cited by other articles:
|
|
 |
|
  M.-F. Tsan and B. Gao Heat shock proteins and immune system J. Leukoc. Biol., June 1, 2009; 85(6): 905 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gao, X. Sun, X. Chen, Y. Wang, B. A. Foster, J. Subjeck, P. B. Fisher, and X.-Y. Wang Secretable Chaperone Grp170 Enhances Therapeutic Activity of a Novel Tumor Suppressor, mda-7/IL-24 Cancer Res., May 15, 2008; 68(10): 3890 - 3898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Kislin, M. T. Marron, G. Li, M. W. Graner, and E. Katsanis Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia FASEB J, July 1, 2007; 21(9): 2173 - 2184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-F. Tsan and Baochong Gao Review: Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors Innate Immunity, February 1, 2007; 13(1): 6 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Warger, N. Hilf, G. Rechtsteiner, P. Haselmayer, D. M. Carrick, H. Jonuleit, P. von Landenberg, H.-G. Rammensee, C. V. Nicchitta, M. P. Radsak, et al. Interaction of TLR2 and TLR4 Ligands with the N-terminal Domain of Gp96 Amplifies Innate and Adaptive Immune Responses J. Biol. Chem., August 11, 2006; 281(32): 22545 - 22553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-Y. Wang, H. Arnouk, X. Chen, L. Kazim, E. A. Repasky, and J. R. Subjeck Extracellular Targeting of Endoplasmic Reticulum Chaperone Glucose-Regulated Protein 170 Enhances Tumor Immunity to a Poorly Immunogenic Melanoma J. Immunol., August 1, 2006; 177(3): 1543 - 1551. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhang, S.-H. Wang, M. E. Lasbury, D. Tschang, C.-P. Liao, P. J. Durant, and C.-H. Lee Toll-Like Receptor 2 Mediates Alveolar Macrophage Response to Pneumocystis murina Infect. Immun., March 1, 2006; 74(3): 1857 - 1864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-E. Park, J. Facciponte, X. Chen, I. MacDonald, E. A. Repasky, M. H. Manjili, X.-Y. Wang, and J. R. Subjeck Chaperoning Function of Stress Protein grp170, a Member of the hsp70 Superfamily, Is Responsible for its Immunoadjuvant Activity Cancer Res., January 15, 2006; 66(2): 1161 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, H. Wang, Z. Yang, T. Kon, J. Zhu, Y. Cao, F. Li, J. Kirkpatrick, C. V. Nicchitta, and C.-Y. Li Enhancement of Cancer Radiation Therapy by Use of Adenovirus-Mediated Secretable Glucose-Regulated Protein 94/gp96 Expression Cancer Res., October 15, 2005; 65(20): 9126 - 9131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Massa, C. Melani, and M. P. Colombo Chaperon and Adjuvant Activity of hsp70: Different Natural Killer Requirement for Cross-Priming of Chaperoned and Bystander Antigens Cancer Res., September 1, 2005; 65(17): 7942 - 7949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zeng, M. W. Graner, S. Thompson, M. Marron, and E. Katsanis Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells Blood, March 1, 2005; 105(5): 2016 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Berwin, Y. Delneste, R. V. Lovingood, S. R. Post, and S. V. Pizzo SREC-I, a Type F Scavenger Receptor, Is an Endocytic Receptor for Calreticulin J. Biol. Chem., December 3, 2004; 279(49): 51250 - 51257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-F. Tsan and B. Gao Endogenous ligands of Toll-like receptors J. Leukoc. Biol., September 1, 2004; 76(3): 514 - 519. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
